ERVEBO (Ebola Zaire Vaccine, Live) – Prescribing Information (merck.com)

• ERVEBO is a live vaccine against Zaire ebolavirus, approved for ages 12 months and older.
• Most common adverse events: injection-site pain, headache, feverishness, myalgia.
• Vaccine virus RNA can be shed; transmission is a theoretical possibility.
• Duration of protection unknown; does not protect against other ebolaviruses or Marburgvirus.

"Official prescribing information for ERVEBO, a vaccine for prevention of disease caused by Zaire ebolavirus in individuals 12 months and older. Includes dosing (single 1 mL intramuscular dose), contraindications (severe allergic reaction), warnings (anaphylaxis, vaccine virus RNA shedding), and common adverse reactions such as injection-site pain, headache, and feverishness. The duration of protection is unknown; the vaccine does not protect against other ebolavirus species or Marburgvirus. Data from clinical trials across age groups are provided."